Astera Labs (ALAB) is trading 5.9% up at $415.00 today after UBS raised its financial estimates and price target, citing an expanding opportunity in CXL technology. - UBS increased ALAB's price target from $205 to $400 and raised revenue expectations for 2027 and 2028 to $2.5 billion and $3.3 billion, respectively. - The upgrade comes amidst a broader recovery in tech and AI sentiment, with investors also buying the dip after a recent pullback driven by valuation concerns and a prior downgrade.